Moleculera Labs Inc.
Diagnosing treatable autoimmune neuropsychiatric illnesses
This article was originally published in Start Up
Moleculera Labs Inc. was founded on the theory that sometimes when psychiatric symptoms appear suddenly in a young person and do not respond well to neuropsychiatric drugs, it could be that an infection has sparked an autoimmune attack on the brain and has triggered PANS or PANDAS. The start-up has developed a diagnostic test to determine if an underlying autoimmune problem is at the heart of the neuropsychiatric symptoms.
You may also be interested in...
After winning US FDA clearance in 2021, Activ Surgical now also received the green light to market its visualization module for surgeons in Europe.
Deal Snapshot: Akeso has already sought to secure FDA approval for its PD-1 inhibitor, but the agency has shown reluctance to approve drugs based on China-only data.
Using artificial intelligence and coronary computed tomography angiography Cleerly is trying to shift cardiology's focus from symptoms-based interventions to prevention and treatment of the underlying vascular disease.